A recently filed lawsuit alleging that a faulty electronic health record system caused patient harm may be among the first in a wave of such cases, even though most experts say the latest EHR systems are better designed than older models.
Two Washington state men have filed a class-action lawsuit against Northwest Hospital & Medical Center in Seattle, claiming the hospital failed to screen them for free or discounted care under the Washington Charity Care Act.
In deciding a case over who should have the upper hand in patent battles, the U.S. Supreme Court delivered a win to generic-drug makers and those hoping to hold down drug prices.
A judge delivered the Federal Trade Commission a major setback last week in one of its biggest hospital cases in years, and experts say the decision could embolden even more hospitals to consolidate.
The U.S. Supreme Court last week unanimously upheld a legal theory now used to bring many fraud cases against providers—but it also tried to outline the limits of that theory so it's not used to go after providers for minor violations.
A recent Broward Health board meeting took an unexpected turn—and led to the confiscation of an unusual device.
A brilliant and beautiful young billionaire. A fast-rising startup with a disruptive medical technology. Allegations the company's product doesn't work. Federal investigations.
"Implied certification" can impose liability where a contractor has engaged in a lie by omission, such as failing to disclose its noncompliance. The decision could bring more False Claims Act cases against healthcare providers.
A former U.S. Food and Drug Administration official has pleaded guilty to tipping off a hedge fund manager to drug developments that allowed the trader to illegally make $25 million in profits from insider trading. An unnamed former CMS official is also implicated in the schemes.
A Mississippi health system has agreed to pour $150 million into its pension system over the next four decades to settle class-action lawsuits alleging it underfunded the plan.
Drugmaker Merck & Co. is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.
Drugmaker Genentech will pay the government $67 million to settle allegations that it oversold the effectiveness of one of its cancer drugs.